SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060075
Filing Date
2024-05-15
Accepted
2024-05-15 08:57:34
Documents
52
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tcrt-20240331.htm   iXBRL 10-Q 1229545
2 EX-10.1 tcrt-ex10_1.htm EX-10.1 669
3 PDF COURTESY COPY tcrt-ex10_1.pdf EX-10.1 203180
4 EX-31.1 tcrt-ex31_1.htm EX-31.1 12814
5 EX-32.1 tcrt-ex32_1.htm EX-32.1 7013
  Complete submission text file 0000950170-24-060075.txt   5210656

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20240331.xsd EX-101.SCH 963077
55 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20240331_htm.xml XML 494708
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33038 | Film No.: 24947421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)